14 June 2022 - Public comment period now open until 13 July 2022; requests to make oral comment during public meeting also being accepted.
The ICER today released a draft evidence report assessing the comparative clinical effectiveness and value of AMX0035 (Amylyx Pharmaceuticals) and oral edaravone (Mitsubishi Tanabe) for the treatment of amyotrophic lateral sclerosis.